CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia

Blood

Volumn 91, Issue 10, 1998, Pages 3943-3951

  Beltinger, Christian ^b   Kurz, Elke ^b   Böhler, Thomas ^b   Schrappe, Martin ^b   Ludwig, Wolf Dieter ^b   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TRANSCRIPTION FACTOR AP 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; ARTICLE; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; T LYMPHOCYTE;

EID: 0032525198     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.10.3943.3943_3943_3951     Document Type: Article

References (52)

1. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
2. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH: Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 335:497, 1990
3. Debatin KM, Goldman CK, Waldmann TA, Krammer PH: APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 81:2972, 1993
4. Debatin KM, Krammer PH: Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent antiapoptotic program. Leukemia 9:815, 1995
5. Karawajew L, Wuchter C, Ruppert V, Drexler H, Gruss HJ, Dörken B, Ludwig WD: Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 11:1245, 1997
6. Nguyen PL, Harris NL, Ritz J, Robertson MJ: Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 148:847, 1995
7. Min YH, Lee S, Lee JW, Chong SY, Hahn JS, Ko YW: Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Haematol 93:928, 1996
8. Lücking-Famira KM, Daniel PT, Möller P, Krammer PH, Debatin KM: APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 8:1825,1994
9. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189,1995
10. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363, 1996
11. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 2:1361, 1996
12. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075, 1996
13. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H: Expression of Fas ligand in liver métastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94:6420, 1997
14. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA: Human lung carcinomas express Fas ligand. Cancer Res 57:1007, 1997
15. Peng SL, Robert ME, Hayday AC, Craft J: A tumor-suppressor function for Fas (CD95) revealed in T Cell-deficient mice. J Exp Med, 184:1149, 1996
16. Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Möröy T: Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E m L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10:2397, 1995
17. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MJ, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1994
18. Cascino I, Papoff G, De Maria R; Testi R; Ruberti G: Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 156:13, 1996
19. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH: Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85:1562, 1995
20. Munker R, Midis G, Owen-Schaub L, Andreff M: Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 10:1531, 1996
21. Rieux-Laucat F, Le-Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347, 1995
22. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935, 1995
23. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643, 1996
24. Bettinardi A, Brugnoni D, Quirosroldan E, Malagoli A, Lagrutta S, Correra A, Notarangelo LD: Missense mutation in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood 89:902, 1997
25. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM, Lenardo MJ, Straus SE: Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341, 1997
26. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
27. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574, 1996
28. Micheau O, Solary E, Hamman A, Martin F, Dimanche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89:783, 1997
29. Landowski TH, Gleason-Guzman MC, Dalton WS: Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89:1854, 1997
30. Friesen C, Fulda S, Debatin KM: Deficient activity of CD95(APO-I/Fas) system in drug resistant cells. Leukemia 11:1833, 1997
31. Herr I, Böhler T, Wilhelm D, Angel P, Debatin KM: Activation of the CD95 (APO-1/Fas) pathway by ceramide mediates radio- and chemotherapy induced apoptosis. EMBO J 16:6200, 1997
32. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM: Crossresistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90:3118, 1997
33. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH: Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935, 1997
34. Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, Bender-Götze C, Dörffel W, Dopfer R, Frey E, Havers W, Henze G, Kühl J, Richter R, Ritter J, Treuner J, Zintl F, Odenwald E, Weite K, Riehm H: Concept and interim analysis of trial ALL-BFM 90 for the treatment of children and adolescents with acute lymphoblastic leukemia: Significance of therapy response in peripheral blood and bone marrow. Klin Padiatr 206:208, 1994
35. Ludwig WD, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H: Ambigous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. Blood 71:1518, 1988
36. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig WD: Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood 86:3097, 1995
37. European Group for the lmmunological Characterization of Leukemias (EGIL): Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB: Proposals for the immunological classification of acute leukemias. Leukemia 9:1783, 1995
38. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampen F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Weite K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
39. Löchner K, Siegler G, Führer M, Greil J, Beck JD, Fey GH, Marschalek R: A specific deletion in the breakpoint cluster region of the ALL-1 gene is associated with acute lymphoblastic T-cell leukemias. Cancer Res 56:2171, 1996
40. Herr I, Balemans L, Böhler T, Walczak H, Debatin KM: Monitoring of CD95 (Apo-1/Fas) ligand expression in human T cells by quantitative RT-PCR. Cell Death Differ 3: 299, 1996
41. Behrmann I, Walczak H, Krammer PH: Structure of the human APO-1 gene. Eur J Immunol 24:3057, 1994
42. Cheng J, Liu C, Koopman WJ, Mountz JD: Characterization of human Fas gene. J Immunol 154:1239, 1995
43. Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J: Identification of a silencer, enhancer and basal promoter region in the human CD95 (Fas/APO-1 ) gene. DNA Cell Biol 14:931, 1995
44. Böhler T, Nedel S, Debatin KM: CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Pediatr Res 41:878, 1997
45. Horgan K, Shaw S: lmmunomagnetic purification of T-cell subpopulations, in Coligan JE, Kruisbeek AM, Margulies, DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York, NY, Wiley, 1997, unit 7.4
46. Itoh, N, Nagata, S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 25:10932, 1993
47. Fiucci G, Ruberti G: Detection of polymorphisms within the FAS cDNA gene sequence by GC-clamp denaturing gel electrophoresis. Immunogenetics 39:437, 1994
48. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Arrufo A, Kiener PA: Identification of amino acid residues important for ligand binding to Fas. J Exp Med 185:1487, 1997
49. Rhoades KL, Golub SH, Economu JS: The regulation of the human tumor necrosis factor-α promoter region in macrophage, T-cell and B-cell lines. J Biol Chem 267:22102, 1992
50. Kroeger KM, Abrahm LJ: Identification of an AP-2 element in the -323 to -285 region of the TNF-α gene. Biochem Mol Biol Int 40:43, 1996
51. Park JH, Kaushansky K, Levitt L: Transcriptional regulation of interleukin 3 (IL3) in primary human T lymphocytes. Roles of AP-1 and ocatamer-binding proteins in control of IL3 gene expression. J Biol Chem 268:6299, 1993
52. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH: The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics 14:179, 1992